OMERS ADMINISTRATION Corp Purchases Shares of 173,350 Bristol Myers Squibb Company $BMY

Key Points

• OMERS Administration Corp. acquired 173,350 Bristol Myers Squibb shares during the second quarter, valued at approximately $9.99 million. Institutional investors collectively own 76.41% of BMY’s outstanding stock.
• Bristol Myers Squibb reported quarterly EPS of $2.04, beating estimates by $0.44, while revenue rose 5.7% year over year to $12.97 billion. The company also maintains a quarterly dividend of $0.63, equivalent to a 3.7% annualized yield.
• Analyst sentiment is broadly positive, with the stock receiving a “Moderate Buy” consensus rating and an average price target of $66.06, despite mixed individual rating changes.

OMERS ADMINISTRATION Corp acquired a new position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 173,350 shares of the biopharmaceutical company's stock, valued at approximately $9,988,000.

Several other institutional investors have also recently made changes to their positions in BMY. Leigh Baldwin & CO. LLC acquired a new stake in Bristol Myers Squibb during the second quarter valued at $530,000. Osmosis Investment Management UK Ltd acquired a new position in shares of Bristol Myers Squibb in the second quarter worth about $16,671,000. Sanctuary Advisors LLC purchased a new stake in shares of Bristol Myers Squibb during the 2nd quarter worth about $22,137,000. Barbara Oil Co. purchased a new stake in shares of Bristol Myers Squibb during the 2nd quarter worth about $2,420,000. Finally, Saranac Partners Ltd acquired a new stake in shares of Bristol Myers Squibb during the 2nd quarter valued at about $421,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol Myers Squibb Stock Performance

NYSE BMY opened at $67.30 on Tuesday. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. The stock's 50 day simple moving average is $60.77 and its 200-day simple moving average is $59.47. The company has a market cap of $137.47 billion, a PE ratio of 14.82, a price-to-earnings-growth ratio of 0.17 and a beta of 0.22. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $68.64.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The firm had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. During the same period in the prior year, the company earned $1.46 EPS. The firm's revenue was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, equities research analysts anticipate that Bristol Myers Squibb Company will post 6.95 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were paid a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 3.7%. The ex-dividend date of this dividend was Thursday, July 2nd. Bristol Myers Squibb's dividend payout ratio (DPR) is currently 55.51%.

Analyst Ratings Changes

BMY has been the topic of a number of recent analyst reports. Argus upgraded Bristol Myers Squibb from a "hold" rating to a "buy" rating and set a $75.00 price target on the stock in a research report on Wednesday, August 5th. Roth Capital initiated coverage on Bristol Myers Squibb in a research note on Wednesday, August 5th. They set a "buy" rating and a $75.00 target price for the company. Jefferies Financial Group cut shares of Bristol Myers Squibb from a "buy" rating to a "hold" rating in a research note on Wednesday, August 5th. Truist Financial reissued a "buy" rating and issued a $70.00 price target (up from $65.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. Finally, Citigroup restated a "neutral" rating and set a $70.00 price objective (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Bristol Myers Squibb presently has an average rating of "Moderate Buy" and a consensus target price of $66.06.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source